Will Vertex’s “pipeline-in-a-product” pay off?That’s the bet behind the company’s $4.9 billion acquisition of Alpine Immune Sciences and its mid-stage IgA nephropathy drug, which is designed to inhibit two key cytokines.
SAN DIEGO — Scientists have long dreamed of creating vaccine-like treatments that could teach the immune system to target tumors. After decades of false starts, that idea is finally getting closer to reality.
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
Alpine Immune to Report Fourth Quarter and Full Year 2023 Financial Results
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences